

Electronic Acknowledgement Receipt

EFS ID:	2800708
Application Number:	10521064
International Application Number:	
Confirmation Number:	6846
Title of Invention:	Injectable depot formulation comprising crystals of iloperidone
First Named Inventor/Applicant Name:	Dierk Wieckhusen
Customer Number:	23550
Filer:	Stephen Franklin Swinton
Filer Authorized By:	
Attorney Docket Number:	VAND-0022-US
Receipt Date:	01-FEB-2008
Filing Date:	12-JAN-2005
Time Stamp:	15:30:30
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 120
RAM confirmation Number	684
Deposit Account	500999
Authorized User	SWINTON, JR.,STEPHEN F

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional fees required under 37 CFR 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed	VAND-0022-US_Supplemental_IDS_02-01-08-PRIMO.pdf	30838 2b4bc417d84157c0e578b4b0711451d ba02a790	no	4
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
2	NPL Documents	Blagden_CrystalEngineering ofActivePharmaceutical_PA.pdf	1155333 5c8c0b3da7bd5d04a779a04aa852b01bfc 8781c3d3	no	14
Warnings:					
Information:					
3	NPL Documents	LingualLinxCertificateOfTranslationAccuracy.pdf	31024 921ce6e61c953c15230857947a5c0ba52 3796e6d	no	1
Warnings:					
Information:					
4	NPL Documents	Miescher_DepotEffectOfCrystall_PA.pdf	336622 557c006d0233f4e93f472a560c570fbd 5258d66	no	18
Warnings:					
Information:					
5	NPL Documents	Pieters_SustainedReleaseProperties_PA.pdf	407472 3d1e6534e949e3baa62b54f50131072d5 90aa5072	no	6
Warnings:					
Information:					
6	NPL Documents	Rodriguez-Spong_GeneralPrinciplesofPharmaceutical_PA.pdf	1776317 a0be94a665302ba429c2a1c08ebc753a 83ab34889	no	34
Warnings:					
Information:					
7	NPL Documents	Schillfarth_AboutTheSymptomaticTreatment_PA.pdf	93945 00204812ba2009c99c2435f6fb1154268 0a26e1	no	11
Warnings:					
Information:					
8	NPL Documents	Shekunov_CrystallizationProcessesinPharmaceutical_PA.pdf	863581 2a85d8da0f778d52a0d5f6c1e6a90b75f a6821a	no	15
Warnings:					

Information:					
9	NPL Documents	Singhal_DrugPolymorphisma ndDosage_PA.pdf	738091	no	13
			529e0311f86497d7be3c222ea3cd2be18 0653ee		
Warnings:					
Information:					
10	NPL Documents	Vippagunta_CrystallineSolid s_PA.pdf	1325167	no	24
			494b964383d44e334b3a57c73932487b 290f85ca		
Warnings:					
Information:					
11		VAND-0022_20080201_resp onse.pdf	130111	yes	13
			644b05126c0a8c985c59ad3914c42726 b23f8b7c05		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment - After Non-Final Rejection		1	1	
	Claims		2	8	
	Applicant Arguments/Remarks Made in an Amendment		9	13	
Warnings:					
Information:					
12	Fee Worksheet (PTO-06)	fee-info.pdf	8180	no	2
			83b781ccac2300b1605f1885c9c337b62 bcd9f056a		
Warnings:					
Information:					
Total Files Size (in bytes):			6896681		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.